RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

08 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

28 6 2024 08:00:14 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 6 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

03 6 2024 16:02:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

03 6 2024 08:02:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

22 5 2024 04:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

09 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

07 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

06 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

29 4 2024 18:30:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

24 4 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 4 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

01 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

25 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

06 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22 2 2024 07:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

22 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 2 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

07 2 2024 08:00:00 提供 Nasdaq GlobeNewswire